TVTX Q2 2022 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$54M-0.8% YoY

Gross Profit

$52M96.2% margin

Operating Income

-$65M-120.8% margin

Net Income

-$67M-123.8% margin

EPS (Diluted)

$-1.05

QoQ Revenue Growth

+11.7%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$37M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$779M

Total Liabilities

$623M

Stockholders' Equity

$157M

Cash & Equivalents

$180M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$54M	$55M	-0.8%
Gross Profit	$52M	$53M	-1.6%
Operating Income	-$65M	-$35M	-85.3%
Net Income	-$67M	-$39M	-71.8%

Revenue Segments

Product

$51M50%

Bile Acid Products

$26M25%

Tiopronin Products

$25M25%